CDC20 and breast cancer: To investigate the resistance performance of the proposed drugs against the state-of-the-art alternative receptors for BC compared to the transcriptome-guided 47 published drugs, we performed molecular docking analysis of our proposed drugs including all published drugs with the top ranked independent receptors (KIF11, RRM2, BUB1, CDC20, FOS, FN1, BUB1B, CCNB2, CCNA2, CDK1, TOP2A, CCNB1, and EGFR) published by others for BC in different 78 articles (see S1 File (Table 3)).